Nervous System Disorder Articles & Analysis
32 news found
One of the reasons for the lack of effective treatments is due to suboptimal penetration of the blood-brain barrier for potential drug candidates into the central nervous system. This results in both poor distribution and efficacy. ...
This is not an insignificant achievement. “Central nervous system disorders are a scourge because they are challenging to treat by their very nature. ...
Kurve Therapeutics has developed a cutting-edge approach to treating central nervous system (CNS) disorders. These debilitating disorders afflict millions of people worldwide, yet they lack effective disease-modifying treatments. ...
Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global population. ...
("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. ...
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies to treat chronic neurological disorders, today announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the Locust Walk Stem Cell Tx Conference, which is being organized in partnership with the Harvard Stem ...
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of preclinical data from its lead inhibitory neuron cell therapy candidate, NRTX-1001. ...
PARIS, FRANCE, March 3, 2022, PRNewswire – Qynapse SAS, a medical technology company commercializing an FDA approved/CE cleared AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to announce that a symposium oral presentation and a poster presentation will be delivered at the upcoming ...
ByQynapse
By revealing the connections between the gut and the brain, the Kallyope platform has been leveraged to generate novel programs spanning several relevant therapeutic areas, including metabolism, immunology and inflammation, and central nervous system disorders. A key element of the Kallyope strategy is to target gut and gut-brain physiology with ...
BOSTON, MA, February 14, 2022, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to present 2 posters at the annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, on ...
ByQynapse
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders, today announced that Cory Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the H.C. ...
Together, with our talented team, we are excited to move to the next chapter of Neurona’s evolution, bringing the company’s pioneering cell therapies to people suffering from chronic disorders of the nervous system.” Dr. Nicholas continued, “Dr. ...
Daily observations and assessments of histopathology, hematology and clinical chemistries at multiple time points post-transplantation did not indicate adverse behavioral effects, or local or systemic toxicities related to NRTX-1001 treatment. The Phase 1/2 clinical trial design is also being presented. ...
BOSTON, MA, November 22, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an artificial intelligence (AI)-powered neuroimaging software platform for central nervous system (CNS) disorders, will unveil its new brand and latest AI developments as a key exhibitor in the AI Showcase at the 107th Radiology ...
ByQynapse
Food and Drug Administration (FDA) for its groundbreaking MoveAgain Brain Computer Interface (BCI) system. There are an estimated 5.35 million1 people in the United States who suffer from paralysis due to central nervous system disorders, autoimmune diseases, and spinal cord injuries. Blackrock’s MoveAgain BCI ...
“We have aligned our corporate strategy and our innovation potential toward health and nutrition, which are areas of systemic importance. In doing so, we are looking to help solve a question of fundamental importance: How do we feed and satisfy the health needs of a growing population in the face of climate change?" ...
ByBayer AG
BOSTON, MA, November 4, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to sponsor the 14th Clinical Trials on Alzheimer’s Disease conference (CTAD) to be held from November 9-12, 2021, in Boston, MA. ...
ByQynapse
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging the gut-brain axis for the discovery and development of small molecule therapeutics with an initial focus on autism spectrum disorder (ASD) and Parkinson’s disease (PD), today announced the appointment of A. ...
Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today the appointment of Bryan Phillips as Senior Vice President, General Counsel, Chief Compliance Officer and ...
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the virtual H.C. ...